| WB | 1/500 - 1/2000 | Human,Mouse,Monkey,Rat |
| IF | 咨询技术 | Human,Mouse,Monkey,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Monkey,Rat |
| ICC | 技术咨询 | Human,Mouse,Monkey,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey,Rat |
| Elisa | 1/10000 | Human,Mouse,Monkey,Rat |
| Aliases | HD2; RPD3; YAF1 |
| Entrez GeneID | 3066 |
| clone | 4D8C3 |
| WB Predicted band size | 55.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey,Rat |
| Immunogen | Purified recombinant fragment of human HDAC2 (AA: 217-327) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于HDAC2抗体的参考文献示例(均为虚构示例，仅用于演示格式)：
1. **文献名称**：*HDAC2 modulates chromatin remodeling in neurodevelopmental disorders*
**作者**：Smith A, et al.
**摘要**：研究使用HDAC2抗体通过免疫沉淀和染色质分析，揭示了HDAC2在神经元分化中的表观遗传调控作用，及其与自闭症相关基因的关联。
2. **文献名称**：*Selective inhibition of HDAC2 in cancer stem cells suppresses tumor growth*
**作者**：Lee B, et al.
**摘要**：通过Western blot和免疫组化(使用HDAC2特异性抗体)，证明靶向HDAC2可抑制结肠癌干细胞自我更新，并提出其作为治疗靶点的潜力。
3. **文献名称**：*Validation of HDAC2 antibody specificity in epigenetic studies*
**作者**：Chen X, et al.
**摘要**：系统评估了多种HDAC2抗体的特异性，通过敲除细胞系验证抗体可靠性，为表观遗传学研究提供实验依据。
4. **文献名称**：*HDAC2-mediated histone deacetylation regulates cardiac hypertrophy*
**作者**：Wang Y, et al.
**摘要**：利用HDAC2抗体进行ChIP-seq分析，发现其在心脏肥大中通过调控特定基因的乙酰化水平影响病理进程。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
Histone deacetylase 2 (HDAC2) is a member of the class I histone deacetylase family, which plays a critical role in epigenetic regulation by removing acetyl groups from histone proteins. This enzymatic activity promotes chromatin condensation, leading to transcriptional repression of target genes. HDAC2 is involved in diverse cellular processes, including cell cycle progression, differentiation, and apoptosis, and its dysregulation has been linked to cancers, neurodegenerative disorders, and metabolic diseases. Studies highlight its role in cancer progression, where overexpression of HDAC2 correlates with poor prognosis and resistance to therapy. In neurodegenerative contexts, reduced HDAC2 levels are associated with impaired synaptic plasticity and memory formation.
HDAC2 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological states. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to investigate HDAC2 protein levels, tissue distribution, and interactions with DNA or other regulatory proteins. Validated HDAC2 antibodies are critical for ensuring specificity, as cross-reactivity with other HDAC isoforms (e.g., HDAC1) can confound results. Researchers also utilize these antibodies to explore the therapeutic potential of HDAC inhibitors, which are being investigated for cancer and neurological treatments. Monoclonal and polyclonal HDAC2 antibodies are available, each offering distinct advantages depending on the experimental design.
×
